Why are Tyrosine Kinases Important Targets for Cancer Therapy?
Given their pivotal role in the progression of cancer, tyrosine kinases are attractive targets for cancer therapy. Inhibiting these enzymes can effectively disrupt the signaling pathways essential for tumor growth and survival. Several tyrosine kinase inhibitors (TKIs) have been developed and are currently used in clinical practice. These include imatinib for chronic myeloid leukemia (CML), gefitinib and erlotinib for non-small cell lung cancer (NSCLC), and trastuzumab for HER2-positive breast cancer.
